In the last trading session, 323.53 million Altamira Therapeutics Ltd (NASDAQ:CYTO) shares changed hands as the company’s beta touched 1.63. With the company’s per share price at $0.28 changed hands at $0.18 or 180.28% during last session, the market valuation stood at $2.47M. CYTO’s last price was a discount, traded about -2153.57% off its 52-week high of $6.31. The share price had its 52-week low at $0.09, which suggests the last value was 67.86% up since then. When we look at Altamira Therapeutics Ltd’s average trading volume, we note the 10-day average is 35.46 million shares, with the 3-month average coming to 1.10 million.
Analysts gave the Altamira Therapeutics Ltd (CYTO) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CYTO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Altamira Therapeutics Ltd’s EPS for the current quarter is expected to be $0.
Altamira Therapeutics Ltd (NASDAQ:CYTO) trade information
Instantly CYTO was in green as seen at the end of in last trading. With action 162.91%, the performance over the past five days has been green. The jump to weekly highs of 0.4780 on Friday, 11/17/23 added 180.28% to the stock’s daily price. The company’s shares are showing year-to-date downside of -94.23%, with the 5-day performance at 162.91% in the green. However, in the 30-day time frame, Altamira Therapeutics Ltd (NASDAQ:CYTO) is 76.99% up. Looking at the short shares, we see there were 0.18 million shares sold at short interest cover period of 0.29 days.
The consensus price target for the stock as assigned by Wall Street analysts is $286.10, meaning bulls need an upside of 99.9% from its current market value. According to analyst projections, CYTO’s forecast low is $286.10 with $286.10 as the target high. To hit the forecast high, the stock’s price needs a -102078.57% plunge from its current level, while the stock would need to soar -102078.57% for it to hit the projected low.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of $59.1 million. 1 analysts are of the opinion that Altamira Therapeutics Ltd’s revenue for the quarter ending Jun 2022 will be $59.1 million.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 57.79%.
Altamira Therapeutics Ltd is expected to release its next quarterly earnings report on September 12.
Morgan Stanley holds the second largest percentage of outstanding shares, with 0.01% or 500.0 shares worth $320.0 as of Jun 29, 2023.
With 943.0 shares estimated at $782.0 under it, the former controlled 0.01% of total outstanding shares.